0
Clinical Investigations in Critical Care: COPD |

Controlled Short-term Trial of Fluticasone Propionate in Ventilator-Dependent Patients With COPD*

Stefano Nava, MD; Maria Laura Compagnoni, PhD
Author and Funding Information

*From the Respiratory Intensive Care Unit (Dr. Nava), Fondazione S. Mougeri, Istituto Scientifico di Pavia, FRCCS, Pavia, Italy; and the Service of Pharmacy (Dr. Compagnoni), Fondazione S. Maugeri, Istituto Scientifico di Montescano, IRCCS, Montescano, Italy.

Correspondence to: Stefano Nava, MD, Respiratory Intensive Care Unit, Fondazione S. Mougeri, Istituto Scientifico di Pavia, IRCCS, Via Ferrata 8, 27100 Pavia, Italy; e-mail: snava@fsm.it



Chest. 2000;118(4):990-999. doi:10.1378/chest.118.4.990
Text Size: A A A
Published online

Background: There is no agreement about the efficacy of systemic corticosteroids in patients with COPD, but corticosteroids often are employed during exacerbations of the disease. The use of systemic or inhaled corticosteroids in patients in stable condition is even more controversial, even though the more severely affected patients seem to respond better. Unfortunately, in this subset of patients, the use of forced expiratory maneuvers frequently fails to detect significant functional response.

Study objectives: We evaluated the short-term effects of an inhaled corticosteroid, fluticasone propionate (FP), on FEV1 and on the mechanical properties of patients in stable condition with severe COPD and chronic hypercapnic respiratory failure who were receiving long-term ventilatory support. This allowed us to measure respiratory mechanics (RM) passively, thereby avoiding any problems linked with voluntary maneuvers.

Design: Randomized, placebo-controlled, crossover study.

Setting: A respiratory ICU.

Patients: Twelve hypercapnic COPD patients (mean [± SD] Paco2, 60 ± 11 mm Hg; mean FEV1, 13 ± 5% predicted; and mean FEV1/FVC, 31 ± 7%) were enrolled.

Interventions: A daily dose of 2,000 μg FP or placebo was administered via metered-dose inhaler during mechanical ventilation for 5 consecutive days. A washout of 72 h was allowed between regimens.

Measurements: End-expiratory and end-inspiratory airway occlusions were performed to assess static intrinsic positive end-expiratory pressure (PEEPi,st), static compliance of the respiratory system (Cst,rs), maximal respiratory resistance (Rmax,rs), and minimal respiratory resistance (Rmin,rs). The bronchodilator response also was assessed by FEV1 level.

Results: No significant changes were found in RM after administration of the placebo. By day 6, FP had induced the following significant decreases: PEEPi,st, 4.3 ± 2.4 to 3.1 ± 1.7 cm H2O (p < 0.01); Rmax,rs, 19.0 ± 6.5 to 14.6 ± 6 cm H2O/L/s (p < 0.001); and Rmin,rs, 14.8 ± 4.2 to 10.5 ± 3.4 cm H2O/L/s (p < 0.001). The Cst,rs and the effective additional resistance of the respiratory system did not change significantly, the latter suggesting that the major effect of FP was on the airway caliber (Rmin,rs). FEV1 changes significantly (p < 0.01) underestimated the bronchodilator response, as compared with changes in Rmin,rs.

Conclusions: We conclude that in patients in stable condition with severe COPD and chronic hypercapnic respiratory failure, a brief trial of FP may induce a bronchodilator response, mainly related to a reduction in airway resistances, that is not detected by the usual pulmonary function tests.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543